Susan Hasty, Publisher
Table of Contents . . . May 12th, 1997Non-Subscriber - Summaries Only
Conference Coverage (AACR) - Adenovirus Mediates Prostate Specific Cancer Gene Therapy
Conference Coverage (AACR) - An Adenovirus Selectively Targets/Kills p53-Deficient Tumors
Conference Coverage (AACR) - Antisense Therapy Under Development as Anticancer Therapeutic
Conference Coverage (AACR) - Antisense VEGF Gene Therapy Explored for Brain Tumors
AIDS Therapies - New Assay Speeds, Improves HIV Monitoring and Drug Testing
AIDS Vaccines - Chimpanzees Protected From HIV-1 Infection By New DNA Vaccine
Alzheimer's Disease - Mitochondrial DNA Mutations Reported as Possible Cause
Cancer Clinical Trials - Trial Tests tgDCC-E1A as Potential Cancer Treatment
Chemotherapy (Side Effects) - Treatment May Cause Temporary Abnormalities in Sperm
Conference Coverage (AACR) - Preliminary Results from p53 Injection of Localized HCC
Conference Coverage (AACR) - p53 Gene Therapy Downregulates Vascular Endothelial Growth Factor
Cystic Fibrosis - NIH Panel Makes Recommendations for Genetic Testing for CF
Diabetes (Genetics) - Gene Discovery May Regenerate Insulin-Producing Cells
Melanoma (Metastatic) - Emory Researchers Advance Gene Therapy Studies for Cancer Treatment
Obesity - Gene Implicated in Weight Modulation
Prostate Cancer (Diagnostics) - Gene Shown To Be Very Early Marker for Cancer
Systemic Lupus Erythematosus (Immunotherapy) - Peptides Prevent Experimental SLE in Mice
Immunotherapy (Anti-Cancer) - "Induction of Antitumor Activity by Immunization with Fusions of Dendritic Cells and Carcinoma Cells."
Antisense Technology - "Effects of Anti-tal-1 Oligodeoxynucleotides in T-ALL Cell Lines."
Antisense Technology - "Specific Inhibition of Influenza Virus RNA Polymerase and Nucleoprotein Genes Expression by Liposomally Endocapsulated Antisense Phosphorothioate Oligonucleotides: Penetration and Localization of Oligonucleotides in Clone 76 Cells
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.